{
 "drug": "Medroxyprogesterone Acetate Tablet",
 "asOf": "2026-10-09",
 "status": "discontinuing",
 "since": "08/31/2026",
 "dayN": 39,
 "cat": "Urology",
 "companies": [
  "Pfizer Inc."
 ],
 "reasons": [],
 "records": [
  {
   "discontinued_date": "08/31/2026",
   "update_type": "New",
   "initial_posting_date": "08/31/2026",
   "package_ndc": "0009-0051-01",
   "generic_name": "Medroxyprogesterone Acetate Tablet",
   "contact_info": "800-533-4535",
   "related_info": "Discontinuation of the manufacture of the drug; Withdrawal from sale expected September 2026.",
   "openfda": {
    "application_number": [
     "NDA011839"
    ],
    "brand_name": [
     "PROVERA"
    ],
    "generic_name": [
     "MEDROXYPROGESTERONE ACETATE"
    ],
    "manufacturer_name": [
     "Pharmacia & Upjohn Company LLC"
    ],
    "product_ndc": [
     "0009-0051",
     "0009-0065",
     "0009-0287"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "MEDROXYPROGESTERONE ACETATE"
    ],
    "rxcui": [
     "1000114",
     "1000124",
     "1000135",
     "1000139",
     "1000141",
     "1000145"
    ],
    "spl_id": [
     "ebcdf2fb-760c-4a9a-80a1-a0c6b21a891a"
    ],
    "spl_set_id": [
     "a586be28-96af-4fed-a13f-9b94fd4c7405"
    ],
    "package_ndc": [
     "0009-0065-01",
     "0009-0287-01",
     "0009-0051-01"
    ],
    "unii": [
     "C2QI4IOI2G"
    ]
   },
   "update_date": "08/31/2026",
   "therapeutic_category": [
    "Urology"
   ],
   "dosage_form": "Tablet",
   "presentation": "PROVERA, Tablet, 10 mg (NDC 0009-0051-01)",
   "company_name": "Pfizer Inc.",
   "status": "To Be Discontinued"
  },
  {
   "discontinued_date": "08/31/2026",
   "update_type": "New",
   "initial_posting_date": "08/31/2026",
   "package_ndc": "0009-0065-01",
   "generic_name": "Medroxyprogesterone Acetate Tablet",
   "contact_info": "800-533-4535",
   "related_info": "Discontinuation of the manufacture of the drug; Withdrawal from sale expected early October 2026.",
   "openfda": {
    "application_number": [
     "NDA011839"
    ],
    "brand_name": [
     "PROVERA"
    ],
    "generic_name": [
     "MEDROXYPROGESTERONE ACETATE"
    ],
    "manufacturer_name": [
     "Pharmacia & Upjohn Company LLC"
    ],
    "product_ndc": [
     "0009-0065",
     "0009-0287",
     "0009-0051"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "ORAL"
    ],
    "substance_name": [
     "MEDROXYPROGESTERONE ACETATE"
    ],
    "rxcui": [
     "1000114",
     "1000124",
     "1000135",
     "1000139",
     "1000141",
     "1000145"
    ],
    "spl_id": [
     "ebcdf2fb-760c-4a9a-80a1-a0c6b21a891a"
    ],
    "spl_set_id": [
     "a586be28-96af-4fed-a13f-9b94fd4c7405"
    ],
    "package_ndc": [
     "0009-0065-01",
     "0009-0287-01",
     "0009-0051-01"
    ],
    "unii": [
     "C2QI4IOI2G"
    ]
   },
   "update_date": "08/31/2026",
   "therapeutic_category": [
    "Urology"
   ],
   "dosage_form": "Tablet",
   "presentation": "PROVERA, Tablet, 2.5 mg (NDC 0009-0065-01)",
   "company_name": "Pfizer Inc.",
   "status": "To Be Discontinued"
  }
 ],
 "firstSeen": "2026-09-03",
 "history": [
  {
   "date": "2026-09-03",
   "kind": "new",
   "to": "discontinuing",
   "text": "Medroxyprogesterone Acetate Tablet appeared on the FDA shortage list (being discontinued)"
  }
 ]
}